Despite reasonably solid gains across most sectors, the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) edged higher by just over 0.1% to 5,561 points today.
There were four shares in particular that did a lot of the heavy lifting, each posting incredibly strong gains for their respective shareholders. Here's why they soared:
Ardent Leisure Group (ASX: AAD) shares surged 14% to $2.85 following the release of its full year results which revealed a 32% jump in net profit after tax to $42 million. As this report states, whilst the strong profit growth is fantastic and will no doubt have excited many investors, it is likely to be the incredible potential of the company's Main Event family entertainment centres in the United States which is the real reason for the buying frenzy.
Ardent Leisure's share price has now rocketed almost 25% in the last five trading days.
Altium Limited (ASX: ALU) shares have jumped almost 13% to $8.25 after reporting a strong full year result. The printed circuit board software provider reported revenue growth of 16.7% to US$93.6 million and normalised earnings-per-share grew a massive 43.5% to 17.9 US cents. With the company turning its attention to achieving market leadership and $200 million revenue by 2020, now could be a great time to look at a long-term investment in my opinion.
Altium shares have risen 76% so far in 2016.
iSentia Group Ltd (ASX: ISD) shares have bolted higher by almost 17% to $3.63. Today's increase came thanks to the tech company reporting solid full year results which revealed a 23.6% rise in net profit after tax to $24.3 million. Driving the strong result was a 51% increase in revenue from its Asia/Rest of the World division. Elsewhere a better-than-expected performance from the recently acquired King Content business was a further boost to revenue.
iSentia's shares are still down 26% year to date despite today's gains.
Sirtex Medical Limited (ASX: SRX) shares jumped a massive 12% to $34.80 after the cancer treatment specialist reported net profit of $53.6 million on revenues of $232.5 million for FY 2016. This represented impressive year on year growth of 33% and 32% respectively. Today's strong result was thanks largely to strong growth in dose sales in its core US market which helped take overall dose sales higher by 16.4% year on year.
Sirtex Medical's share price is still down around 13% in 2016.
